# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-24-022721
Filing Date
2024-04-29
Accepted
2024-04-29 08:46:38
Documents
6
Period of Report
2024-06-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | ny20022295x2_def14a.htm | DEF 14A | 549691
2 |  | logo_gyre.jpg | GRAPHIC | 26811
3 |  | ny20022295x2_pc01x1.jpg | GRAPHIC | 656089
4 |  | ny20022295x2_pc02x1.jpg | GRAPHIC | 701124
5 |  | ny20022295x2_pvp01.jpg | GRAPHIC | 144669
6 |  | ny20022295x2_pvp02.jpg | GRAPHIC | 149456
| Complete submission text file | 0001140361-24-022721.txt |  | 2860843

Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-51173 | Film No.: 24886801
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)